Evidence map›Paper›PMID 27049708›Full record

ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2015

HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT.

Angelo Alves de Mattos, Patrícia dos Santos Marcon, Fernanda Schild Branco de Araújo, Gabriela Perdomo Coral, Cristiane Valle Tovo

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Expression of hnRNPK & Claudin-4 in HCV-Induced Early HCC and Adjacent Liver Tissue.Open access Macedonian journal of medical sciences · 2017
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Angelo Alves de MattosUniversidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
Patrícia dos Santos MarconUniversidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
Fernanda Schild Branco de AraújoUniversidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
Gabriela Perdomo CoralUniversidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.
Cristiane Valle TovoUniversidade Federal de Ciências da Saúde de Porto Alegre, RS, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic infection by hepatitis C virus (HCV) is one of the main risk factors for the development of liver cirrhosis and hepatocellular carcinoma. However, the emergence of hepatocellular carcinoma (HCC) in non-cirrhotic HCV patients, especially after sustained virological response (SVR) is an unusual event. Recently, it has been suggested that HCV genotype 3 may have a particular oncogenic mechanism, but the factors involved in these cases as well as the profile of these patients are still not fully understood. Thus, we present the case of a non-cirrhotic fifty-year-old male with HCV infection, genotype 3a, who developed HCC two years after treatment with pegylated-interferon and ribavirin, with SVR, in Brazil.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularDrug Therapy, CombinationHepacivirusHepatitis CHumansInterferon-alphaLiver NeoplasmsMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRibavirinTreatment OutcomeAntiviral AgentsInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirin

Identifiers

PMID27049708
PMCPMC4727140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.